Hanson & Doremus Investment Management Buys 3,903 Shares of Novartis AG $NVS

Posted by Geri Gentry on Jun 23rd, 2026

Hanson & Doremus Investment Management boosted its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 624.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 4,528 shares of the company’s stock after buying an additional 3,903 shares during the quarter. Hanson & Doremus Investment Management’s holdings in Novartis were worth $692,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in NVS. SG Americas Securities LLC bought a new stake in shares of Novartis in the 1st quarter valued at $537,000. Warren Street Wealth Advisors LLC bought a new position in Novartis during the first quarter worth $204,000. Smith Salley Wealth Management grew its holdings in Novartis by 14.7% in the first quarter. Smith Salley Wealth Management now owns 3,892 shares of the company’s stock worth $595,000 after purchasing an additional 500 shares during the period. Evolve Private Wealth LLC grew its holdings in Novartis by 10.1% in the first quarter. Evolve Private Wealth LLC now owns 22,574 shares of the company’s stock worth $3,448,000 after purchasing an additional 2,069 shares during the period. Finally, Monarch Capital Management Inc. bought a new stake in Novartis in the first quarter valued at $214,000. Institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

NVS opened at $148.85 on Tuesday. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. The company has a market capitalization of $284.03 billion, a price-to-earnings ratio of 21.33, a P/E/G ratio of 2.59 and a beta of 0.46. The firm’s fifty day moving average price is $148.98 and its two-hundred day moving average price is $149.02.

Novartis (NYSE:NVS – Get Free Report) last posted its earnings results on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). The firm had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.Novartis’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.28 EPS. As a group, analysts anticipate that Novartis AG will post 8.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Wednesday, March 11th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Morgan Stanley increased their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Finally, Sanford C. Bernstein raised Novartis to a “hold” rating in a research note on Thursday, March 19th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Novartis currently has a consensus rating of “Hold” and an average price target of $141.20.

Check Out Our Latest Stock Analysis on Novartis

Novartis Profile

(Free Report)

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

Hanson & Doremus Investment Management Buys 3,903 Shares of Novartis AG $NVS

Novartis Price Performance

Wall Street Analysts Forecast Growth

Novartis Profile

Further Reading

You might be interested in: